Skip to content
Clinical Trials – home

A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE): An Influenza Vaccine Component

0 / 1
trials open to patients / all trials
21+
Countries

In short

Clinical trials are currently underway to assess the effectiveness and safety of an influenza vaccine containing the A/Darwin/6/2021(H3N2)-Like Strain. This strain, specifically A/Darwin/11/2021 (Wild Type), is one of four viral components in the Flucelvax Tetra vaccine. The trials aim to provide valuable insights into the vaccine's ability to protect against seasonal influenza, particularly the H3N2 subtype.

At a glance

Vaccine Name
Flucelvax Tetra
Manufacturer
Seqirus Netherlands B.V.
Viral Strains
A/Darwin/6/2021(H3N2)-Like Strain (A/Darwin/11/2021, Wild Type), B/Phuket/3073/2013-like virus, B/Austria/1359417/2021-like strain, A/Wisconsin/67/2022 (H1N1)pdm09-like strain
Administration
Intramuscular injection
Formulation
Suspension for injection in pre-filled syringe
Dose
0.5 ml
Authorization
European Union and Norway
ATC Code
J07BB02 (Influenza, purified antigen)

What is A/DARWIN/6/2021(H3N2)-LIKE STRAIN?

A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE) is a component of the influenza vaccine known as Flucelvax Tetra. This strain is specifically designed to protect against a particular type of influenza virus that belongs to the H3N2 subtype. Influenza viruses are constantly changing, which is why vaccine compositions are updated regularly to match the circulating strains.

Vaccine Composition

Flucelvax Tetra is a quadrivalent vaccine, which means it contains four different influenza virus strains. The vaccine composition includes:

  • A/DARWIN/6/2021(H3N2)-LIKE STRAIN (A/DARWIN/11/2021, WILD TYPE)
  • A/WISCONSIN/67/2022 (H1N1)PDM09-LIKE STRAIN (A/GEORGIA/12/2022 CVR-167)
  • B/AUSTRIA/1359417/2021-LIKE STRAIN (B/SINGAPORE/WUH4618/2021)
  • B/PHUKET/3073/2013-LIKE VIRUS (B/SINGAPORE/INFTT-16-0610/2016, WILD TYPE)

Each of these strains is chosen to provide broad protection against the most likely circulating influenza viruses for a given flu season.

How It Works

The A/DARWIN/6/2021(H3N2)-LIKE STRAIN, along with the other strains in the vaccine, works by stimulating your immune system to produce antibodies against these specific influenza viruses. When you're exposed to these viruses in the future, your body is better prepared to fight them off, reducing your risk of getting the flu or experiencing severe symptoms if you do get infected.

Administration

Flucelvax Tetra, which contains the A/DARWIN/6/2021(H3N2)-LIKE STRAIN, is administered as an intramuscular injection. This means the vaccine is injected directly into a muscle, usually in the upper arm for adults. The typical dose is 0.5 ml, given once per flu season.

Effectiveness

The effectiveness of influenza vaccines, including the A/DARWIN/6/2021(H3N2)-LIKE STRAIN component, can vary from year to year. This is because the circulating influenza viruses may change or new strains may emerge. However, even when the vaccine is not a perfect match to circulating viruses, it can still provide some protection and may help reduce the severity of symptoms if you do get the flu.

Safety

Flucelvax Tetra, including the A/DARWIN/6/2021(H3N2)-LIKE STRAIN component, has been tested for safety and efficacy. Like all vaccines, it can cause side effects, although not everyone experiences them. Common side effects may include pain at the injection site, headache, fatigue, and muscle aches. Serious allergic reactions are rare but possible. Always consult with your healthcare provider about the benefits and risks of vaccination for your individual situation.

Questions people often ask

Conditions where A/Darwin/6/2021(H3N2)-Like Strain (A/Darwin/11/2021, Wild Type) is being studied

Each condition opens its own overview and trial list

Trials with A/Darwin/6/2021(H3N2)-Like Strain (A/Darwin/11/2021, Wild Type)

Recruiting trials first

See all 1 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).